Theriva Biologics (TOVX)
Develops stroma-degrading oncolytic viruses for difficult-to-treat solid tumors.
Something off on this page? Send us feedback.
Develops VCN-01 and related oncolytic viruses for solid tumors, using a Spain-based research organization and external clinical and manufacturing networks; no products are approved or sold.
Develops oncolytic adenoviruses for difficult-to-treat solid tumors, centered on VCN-01, a systemically administered virus designed to selectively replicate in tumor cells, degrade protective tumor stroma, and support co-administered therapies and an antitumor immune response. Its clinical work spans metastatic pancreatic cancer, retinoblastoma, and head-and-neck cancer, with preclinical VCN-X programs extending the platform.
Coordinates corporate functions from Maryland and oncology research and clinical development from Spain. Virus-process development occurs in Spain, while clinical and prospective commercial manufacturing, release testing, and much of clinical execution depend on external CDMOs, CROs, sites, investigators, licensors, and academic hospitals.
No products are approved or commercially sold; product revenue requires clinical progress, regulatory approval, manufacturing, and commercialization capability. The funded strategy is concentrated in VCN-01, while future work also depends on financing, partner support, licensed intellectual property, and United States and European regulatory processes.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.3M · Total debt $3.6M · Total assets $34.9M · Shareholders' equity $12.2M
- Revenue
- $0
- Operating income
- −$3.3M
- Net income
- −$3.2M
No dividends on record.
| Institutions | 4.32% | 1.98M shares | |
|---|---|---|---|
| 24 holders · as of Jun 30, 2026 | |||
| Other | 95.68% | 43.91M shares | |
| remainder | |||
45.89M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 1.06% | 486,179 | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 0.72% | 331,922 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.64% | 294,021 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.53% | 241,780 | as of Jun 30, 2026 |
Ikarian Capital, LLCInstitution | 0.24% | 112,076 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Oncolytics Biotech
Closest listed rival in systemic, first-line mPDAC viral combinations.
- Candel Therapeutics
Direct PDAC rival with a clinically tested adenoviral immunotherapy.
- Calidi Biotherapeutics
Systemic enveloped-virus platform rival for metastatic solid tumors.
- Genelux
Late-stage vaccinia platform competing for oncolytic-virus partners.
- Replimune Group
HSV-1 platform rival for oncolytic-immunotherapy capital and partners.
- CG Oncology
Bladder-focused adenovirus peer in the broader oncolytic-virus field.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Theriva Biologics | $0.2350 | +1.82% | $10.6M | — | — | 35.3 | +94.8% |
| Oncolytics Biotech | $0.6714 | −5.87% | $71.6M | — | — | — | — |
| Candel Therapeutics | $11.60 | −2.15% | $868.3M | — | — | — | — |
| Calidi Biotherapeutics | $1.11 | 0.00% | $511.1K | — | — | — | — |
| Genelux | $2.52 | −3.64% | $117.0M | — | — | 14,629.2 | −98.2% |
| Replimune Group | $12.75 | −5.37% | $1.13B | — | — | — | — |
| CG Oncology | $73.96 | −4.86% | $6.86B | — | — | 1,101.0 | — |
| Median | — | — | 7,865.1 | −98.2% |